{"id":1829,"date":"2023-03-03T10:08:48","date_gmt":"2023-03-03T10:08:48","guid":{"rendered":"http:\/\/proboostnow.eu\/?page_id=1829"},"modified":"2024-07-18T16:36:18","modified_gmt":"2024-07-18T16:36:18","slug":"tpa-v-terapii-fiv-vedecke-studie","status":"publish","type":"page","link":"https:\/\/proboostnow.eu\/en_us\/tpa-v-terapii-fiv-vedecke-studie\/","title":{"rendered":"TPA v terapii FIV, v\u011bdeck\u00e9 studie"},"content":{"rendered":"<div class=\"banner has-hover\" id=\"banner-1732198183\">\n          <div class=\"banner-inner fill\">\n        <div class=\"banner-bg fill\" >\n            <img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"842\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/cat-gd1f75ab10_1920-1024x845.jpg\" class=\"bg attachment-large size-large\" alt=\"FIV TPA studie\" \/>                                    \n                    <\/div>\n\t\t\n        <div class=\"banner-layers container\">\n            <div class=\"fill banner-link\"><\/div>            \n\n   <div id=\"text-box-2000609444\" class=\"text-box banner-layer x50 md-x50 lg-x50 y50 md-y50 lg-y50 res-text\">\n                                <div class=\"text-box-content text dark\">\n              \n              <div class=\"text-inner text-center\">\n                  \n\n<h2 class=\"entry-title\" style=\"text-align: center;\">TPA v terapii Felinn\u00ed imunodeficience FIV<\/h2>\n<h4 class=\"entry-title\" style=\"text-align: center;\">d\u00e1vkov\u00e1n\u00ed, v\u011bdeck\u00e9 studie<\/h4>\n\n              <\/div>\n           <\/div>\n                            \n<style>\n#text-box-2000609444 {\n  width: 95%;\n}\n#text-box-2000609444 .text-box-content {\n  font-size: 100%;\n}\n<\/style>\n    <\/div>\n \n\n        <\/div>\n      <\/div>\n\n            \n<style>\n#banner-1732198183 {\n  padding-top: 500px;\n}\n<\/style>\n  <\/div>\n\n\n\t<div id=\"gap-1661108902\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1661108902 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div id=\"gap-1121161624\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1121161624 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n<div class=\"row\"  id=\"row-754123588\">\n\n\n\t<div id=\"col-1090053159\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-3906690496\" class=\"text\">\n\t\t\n\n<p>FIV naru\u0161uje imunitn\u00ed syst\u00e9m ko\u010dek t\u00edm, \u017ee infikuje mnoho typ\u016f bun\u011bk, v\u010detn\u011b CD4+ a CD8+ T lymfocyt\u016f, B lymfocyt\u016f a makrof\u00e1g\u016f. Ke kone\u010dn\u00e9mu kolapsu doch\u00e1z\u00ed vy\u010derp\u00e1n\u00edm T-pomocn\u00fdch (CD4+) bun\u011bk. B\u011bhem nemoci doch\u00e1z\u00ed k destrukci brzl\u00edku.<\/p>\n<p>D\u00edky velk\u00e9 podobnosti FIV ko\u010dek a HIV u lid\u00ed, co\u017e jsou choroby, kter\u00e9 ob\u011b zp\u016fsobuj\u00ed lentiviry a maj\u00ed mnoho spole\u010dn\u00fdch symptom\u016f, se dostalo onemocn\u011bn\u00ed ko\u010dek do pop\u0159ed\u00ed z\u00e1jmu v\u011bdc\u016f jako modelov\u00fd organismus vhodn\u00fd pro v\u00fdzkum lidsk\u00e9 nemoci. I d\u00edky tomu jsou dnes experiment\u00e1ln\u011b pou\u017e\u00edv\u00e1na modern\u00ed antivirotika vyvinut\u00e1 na HIV s jistou m\u00edrou \u00fasp\u011b\u0161nosti i u ko\u010dek naka\u017een\u00fdch virem felinn\u00ed imunodeficience. (Raltegravir, Bictegravir, Tipranavir, RetroMAD1\u2026).<\/p>\n<p>Doufejme, \u017ee brzo se objev\u00ed stejn\u011b \u00fa\u010dinn\u00e9 antivirotikum, jak\u00e9 dnes ji\u017e zachra\u0148uje \u017eivoty statis\u00edc\u016fm ko\u010dek nemocn\u00fdch infek\u010dn\u00ed peritonitidou.<\/p>\n<p>Druhou cestou, kter\u00e1 je velmi \u00fa\u010dinn\u00e1 i u tak z\u00e1va\u017en\u00fdch onemocn\u011bn\u00ed, jak\u00fdmi je rakovina v podob\u011b biologick\u00e9 l\u00e9\u010dby, je ovlivn\u011bn\u00ed sebez\u00e1chovn\u00fdch mechanism\u016f vlastn\u00edho imunitn\u00edho syst\u00e9mu nemocn\u00e9ho zv\u00ed\u0159ete. Tento v\u011bdeck\u00fd p\u0159\u00edstup t\u011b\u017e\u00ed ze studia miliony let cizelovan\u00fdch p\u0159irozen\u00fdch mechanism\u016f, kter\u00e9 udr\u017euj\u00ed \u017eivot na planet\u011b i p\u0159es vz\u00e1jemnou kompetici vir\u016f a \u017eivo\u010dich\u016f.<\/p>\n<p>D\u00edky neuv\u011b\u0159iteln\u00fdm objev\u016fm na poli modern\u00ed imunologie v posledn\u00edch n\u011bkolika dek\u00e1d\u00e1ch se diametr\u00e1ln\u011b zm\u011bnily trendy sou\u010dasn\u00e9 medic\u00edny.<\/p>\n<p>Thymov\u00fd glykoprotein TPA (=LCTI) byl studov\u00e1n pr\u00e1v\u011b na ko\u010di\u010d\u00edm FIV modelu ve vztahu k hum\u00e1nn\u00edmu onemocn\u011bn\u00ed AIDS. D\u00edky tomu bylo zji\u0161t\u011bno, \u017ee velmi z\u00e1sadn\u00edm zp\u016fsobem p\u0159irozen\u011b ovliv\u0148uje pr\u016fb\u011bh i progn\u00f3zu onemocn\u011bn\u00ed a v mnoha p\u0159\u00edpadech dokonce d\u00edky mobilizaci imunitn\u00edch proces\u016f do\u0161lo k \u00fapln\u00e9 eliminaci virov\u00e9 infekce.<\/p>\n\t\t\n<style>\n#text-3906690496 {\n  color: rgb(0,0,0);\n}\n#text-3906690496 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n<div class=\"row\"  id=\"row-1109589074\">\n\n\n\t<div id=\"col-2133617968\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-1595738563\" class=\"text\">\n\t\t\n\n<h5>D\u00e1vkov\u00e1n\u00ed:<\/h5>\n<p><strong>Je nutn\u00e9 \u00fazce spolupracovat s veterin\u00e1\u0159em a po cel\u00fd \u017eivot ko\u010di\u010d\u00edho pacienta v\u011bnovat zv\u00fd\u0161enou pozornost jeho aktu\u00e1ln\u00edmu zdravotn\u00edmu stavu. Je zcela z\u00e1sadn\u00ed ve\u0161ker\u00e9 zdravotn\u00ed komplikace v prvn\u00ed \u0159ad\u011b \u0159e\u0161it dostupnou symptomatickou l\u00e9\u010dbou pod dohledem veterin\u00e1\u0159e. Pokud m\u00e1 jak\u00e1koliv l\u00e9\u010dba v\u00e9st k \u00fasp\u011bchu, mus\u00ed b\u00fdt komplexn\u00ed a vyu\u017e\u00edt v\u0161echny mo\u017enosti, kter\u00e9 m\u00e1 modern\u00ed veterin\u00e1rn\u00ed medic\u00edna k dispozici. ProBoost nen\u00ed univerz\u00e1ln\u00ed z\u00e1zra\u010dn\u00fd lektvar na v\u0161echny neduhy a i kdy\u017e je nesm\u00edrn\u011b \u00fa\u010dinn\u00fd, je t\u0159eba postupovat racion\u00e1ln\u011b a pokud ko\u010di\u010dka pot\u0159ebuje \u0159e\u0161it z\u00e1va\u017en\u00fd zdravotn\u00ed probl\u00e9m, je nutn\u00e9 j\u00ed poskytnout v\u0161echnu dostupnou l\u00e9\u010dbu. U tak z\u00e1va\u017en\u00e9 diagn\u00f3zy, jakou je FIV nen\u00ed prostor na neuv\u00e1\u017een\u00e9 experimenty. ProBoost p\u016fsob\u00ed na p\u0159\u00ed\u010dinu nemoci, jej\u00ed fyzick\u00e9 n\u00e1sledky m\u016f\u017ee mnohdy pozitivn\u011b ovlivnit tak\u00e9 a urychlit uzdraven\u00ed, ale bylo by nap\u0159\u00edklad v p\u0159\u00edpad\u011b bakteri\u00e1ln\u00ed komplikace krajn\u011b nezodpov\u011bdn\u00e9 nepou\u017e\u00edt antibiotika a podobn\u011b&#8230; V p\u0159\u00edpad\u011b v\u00e1\u017en\u00fdch zdravotn\u00edch pot\u00ed\u017e\u00ed je nutn\u00e9 pacienta stabilizovat v\u0161emi dostupn\u00fdmi prost\u0159edky. Dal\u0161\u00ed imunostimulanty nebo imunomodul\u00e1tory je ale t\u0159eba pou\u017e\u00edvat s rozvahou a s ohledem na zp\u016fsob, jak\u00fdm zasahuj\u00ed do imunitn\u00edch proces\u016f a jak\u00fdm zp\u016fsobem mohou ovlivnit aktu\u00e1ln\u00ed zdravotn\u00ed stav. Nen\u00ed nap\u0159\u00edklad rozumn\u00e9 stimulovat nespecificky imunitu, kdy\u017e m\u00e1 ko\u010di\u010dka vysok\u00fd titr protil\u00e1tek proti FeCoV, nebo neuv\u00e1\u017een\u00fdm v\u00fdb\u011brem imunostimulantu prohloubit chybnou autoimunitn\u00ed\u00a0 reakci.<\/strong><\/p>\n<p>P\u016fvodn\u00ed studie uv\u00e1d\u011bla mnohaletou bezp\u0159\u00edznakovou remisi po t\u0159ech inicia\u010dn\u00edch injek\u010dn\u00edch d\u00e1vk\u00e1ch a pot\u00e9 m\u011bl b\u00fdt LTCI individu\u00e1ln\u011b aplikov\u00e1n jednou za jeden a\u017e dva m\u011bs\u00edce, v praxi byly mnohdy nutn\u00e9 aplikace i v krat\u0161\u00edm intervalu, nap\u0159\u00edklad v t\u011b\u017ek\u00fdch p\u0159\u00edpadech jednou t\u00fddn\u011b, v\u017edy tedy individu\u00e1ln\u011b podle stavu pacienta.\u00a0<\/p>\n<p>D\u00e1vkov\u00e1n\u00ed ProBoostu, doporu\u010duj\u00ed veterin\u00e1\u0159i pro dosp\u011blou ko\u010dku se zdravotn\u00edmi probl\u00e9my p\u016fl s\u00e1\u010dku na den, l\u00e9pe ve dvou d\u00e1vk\u00e1ch po 12 hodin\u00e1ch a po \u010dtvrtin\u011b s\u00e1\u010dku. N\u00e1stup \u00fa\u010dinku trv\u00e1 trochu d\u00e9le, ne\u017e p\u0159i injek\u010dn\u00ed aplikaci T-Cyte, ale TPA je v krvi pom\u011brn\u011b stabiln\u00ed a tak sta\u010d\u00ed po men\u0161\u00edch d\u00e1vk\u00e1ch pr\u016fb\u011b\u017en\u011b dopl\u0148ovat k zaji\u0161t\u011bn\u00ed dostate\u010dn\u00e9 koncentrace pro pot\u0159eby aktivace lymfocyt\u016f a vyvol\u00e1n\u00ed apopt\u00f3zy naka\u017een\u00fdch bun\u011bk. Jakmile je zv\u00ed\u0159e po n\u011bkolika t\u00fddnech stabilizovan\u00e9, sta\u010d\u00ed udr\u017eovac\u00ed d\u00e1vka, kter\u00e1 z\u00e1vis\u00ed na posouzen\u00ed zdravotn\u00edho stavu konkr\u00e9tn\u00ed ko\u010di\u010dky, zejm\u00e9na vyhodnocen\u00ed krevn\u00edho obrazu \u2013 hladina b\u00edl\u00fdch krvinek\u2026. Doporu\u010dujeme d\u00e1le pokra\u010dovat alespo\u0148 v minim\u00e1ln\u00ed udr\u017eovac\u00ed d\u00e1vce, kter\u00e1 z\u00e1vis\u00ed na posouzen\u00ed individu\u00e1ln\u00edho zdravotn\u00edho stavu a m\u016f\u017ee b\u00fdt nap\u0159\u00edklad \u010dtvrt s\u00e1\u010dku na den nebo jednou a\u017e dvakr\u00e1t t\u00fddn\u011b. I zcela zdrav\u00e9mu jedinci je pod\u00e1v\u00e1n\u00ed TPA ka\u017ed\u00fd den pro pos\u00edlen\u00ed imunity prosp\u011b\u0161n\u00e9, nehroz\u00ed p\u0159ed\u00e1vkov\u00e1n\u00ed, tak\u017ee po prod\u011bl\u00e1n\u00ed tak z\u00e1va\u017en\u00e9 infekce, jakou je FeLV nebo FIV je ur\u010dit\u011b na m\u00edst\u011b pokra\u010dovat v pod\u00e1v\u00e1n\u00ed TPA ve frekvenci, kter\u00e1 je v podstat\u011b na rozhodnut\u00ed majitele ide\u00e1ln\u011b po konzultaci s veterin\u00e1\u0159em, kter\u00fd vyhodnot\u00ed kondici pacienta. V pr\u016fb\u011bhu \u017eivota se m\u016f\u017ee s d\u00e1vkou pracovat podle konkr\u00e9tn\u00ed situace. Pokud se v\u00fdsledky zhor\u0161\u00ed, nasad\u00ed se vy\u0161\u0161\u00ed d\u00e1vka, pokud budou v\u00fdsledky excelentn\u00ed, m\u016f\u017ee se podpora imunity pacienta sn\u00ed\u017eit na minimum. Pokud b\u011b\u017e\u00ed sou\u010dasn\u011b n\u011bjak\u00e1 v\u00e1\u017en\u00e1 autoimunita, m\u016f\u017ee b\u00fdt d\u00e1vkov\u00e1n\u00ed klidn\u011b jeden nebo dva s\u00e1\u010dky na den. Ka\u017ed\u00fd majitel mus\u00ed sledov\u00e1n\u00edm odpov\u011bdi na imunostimulaci \u201cvytitrovat\u201d optim\u00e1ln\u00ed d\u00e1vkov\u00e1n\u00ed pro vymizen\u00ed pot\u00ed\u017e\u00ed.<\/p>\n<p>V po\u010d\u00e1te\u010dn\u00edm st\u00e1diu infekce doporu\u010dujeme pod\u00e1vat l\u00e9pe p\u016fl nejm\u00e9n\u011b \u010dtvrt s\u00e1\u010dku na den a pr\u016fb\u011b\u017en\u011b po n\u011bkolika t\u00fddnech nebo m\u011bs\u00edc\u00edch po konzultaci s veterin\u00e1\u0159em prov\u00e9st laboratorn\u00ed ov\u011b\u0159en\u00ed pr\u016fb\u011bhu infekce v nad\u011bji, \u017ee se nad nemoc\u00ed poda\u0159\u00ed zv\u00edt\u011bzit. Tento proces m\u016f\u017ee trvat t\u00fddny nebo i m\u011bs\u00edce \u010di roky. Je t\u0159eba se ozbrojit trp\u011blivost\u00ed a vytrvat v nad\u011bji, \u017ee siln\u00e1 imunita podpo\u0159en\u00e1 ProBoostem p\u0159esn\u011b na spr\u00e1vn\u00e9m m\u00edst\u011b sama dok\u00e1\u017ee nad nemoc\u00ed zv\u00edt\u011bzit. Vy\u0161\u0161\u00ed pravideln\u00e9 pod\u00e1v\u00e1n\u00ed ProBoostu je mo\u017en\u00e9 tak\u00e9 pokud se chceme pokusit zm\u00edrnit nebo potla\u010dit pr\u016fb\u011b\u017en\u00e9 komplikace onemocn\u011bn\u00ed, jako je velmi \u010dast\u00e1 gingivostomatitida a podobn\u011b.<\/p>\n<p>Samoz\u0159ejm\u011b je nasnad\u011b u\u017eite\u010dn\u00e1 mo\u017enost krom\u011b pod\u00e1v\u00e1n\u00ed ProBoostu i dopln\u011bn\u00ed l\u00e9\u010dby o dal\u0161\u00ed l\u00e9\u010debn\u00e9 a nutri\u010dn\u00ed p\u0159\u00edpravky a dal\u0161\u00ed produkty na podporu imunity, jako jsou betaglukany atp.<\/p>\n<p>V r\u00e1mci l\u00e9\u010dby imunodeficientn\u00edch pacient\u016f FeLV, FIV, po terapii FIP jsou \u010dasto pou\u017e\u00edv\u00e1ny podp\u016frn\u00e9 prost\u0159edky bez l\u00e9ka\u0159sk\u00e9ho p\u0159edpisu. D\u016frazn\u011b varujeme a\u00a0 v\u017edy u tak v\u00e1\u017en\u00e9 nemoci doporu\u010dujeme konzultaci s odborn\u00edkem. Jak u\u017e poznali pejsek s ko\u010di\u010dkou, kdy\u017e pekli dort, i v\u0161eho dobr\u00e9ho m\u016f\u017ee b\u00fdt p\u0159\u00edli\u0161.<\/p>\n<p>Imunoglukany, co\u017e je komplex polysacharid\u016f s \u00fa\u010dinkem na nespecifick\u00e9 imunitn\u00ed procesy, lze samoz\u0159ejm\u011b doporu\u010dit. Pokud zvol\u00edte variantu sirupu s p\u0159id\u00e1van\u00fdm vitam\u00ednem C, je t\u0159eba jist\u00e9 opatrnosti. Chronick\u00e1 aplikace vitam\u00ednu C ve vysok\u00e9 d\u00e1vce m\u016f\u017ee v\u00fdznamn\u011b okyselit mo\u010d a vzniknou tak probl\u00e9my s oxal\u00e1ty. V p\u0159im\u011b\u0159en\u00e9m mno\u017estv\u00ed lze vitamin C samoz\u0159ejm\u011b i dlouhodob\u011b jednozna\u010dn\u011b doporu\u010dit. Dlouhodob\u00e1 trval\u00e1 stimulace nespecifick\u00e9 imunity p\u0159edkl\u00e1d\u00e1n\u00edm t\u011bchto imunogenn\u00edch biologicky aktivn\u00edch polysacharid\u016f m\u016f\u017ee \u010dasem v\u00e9st k vy\u010derp\u00e1n\u00ed a poklesu v\u00fdsledn\u00e9ho efektu, proto je l\u00e9pe u\u017e\u00edv\u00e1n\u00ed v\u017edy na ur\u010ditou dobu p\u0159eru\u0161it.\u00a0<\/p>\n<p>Hojn\u011b jsou v dobr\u00e9 v\u00ed\u0159e pou\u017e\u00edv\u00e1ny a doporu\u010dov\u00e1ny r\u016fzn\u00e9 produkty z bylinek atp.\u00a0 Hlavn\u011b u chronick\u00fdch pacient\u016f p\u0159ed dlouhodob\u00fdm pod\u00e1v\u00e1n\u00edm se v\u0161\u00ed d\u016fraznost\u00ed varujeme! Je t\u0159eba si uv\u011bdomit, \u017ee v\u00fdta\u017eky z rostlin jsou vlastn\u011b l\u00e9ky p\u0159\u00edrodn\u00edho p\u016fvodu a jako takov\u00e9 se mus\u00ed pou\u017e\u00edvat s rozvahou a v\u017edy po konzultaci s odborn\u00edky. Kr\u00e1tkodob\u011b a v p\u0159im\u011b\u0159en\u00e9m mno\u017estv\u00ed jsou nesm\u00edrn\u011b u\u017eite\u010dn\u00e9, v\u017edy ale s ohledem na znalost vedlej\u0161\u00edch rizik a ne\u017e\u00e1douc\u00edho p\u016fsoben\u00ed.\u00a0<\/p>\n<p>N\u011bkolik p\u0159\u00edklad\u016f rostlin, kter\u00e9 jsou sou\u010d\u00e1st\u00ed bylinn\u00fdch prepar\u00e1t\u016f doporu\u010dovan\u00fdch u ko\u010di\u010dek s FIV a FeLV na pos\u00edlen\u00ed imunity:<\/p>\n<p>Aloe vera je klenot mezi l\u00e9\u010div\u00fdmi rostlinami. Je dob\u0159e si ale zjistit, zda v\u00fdrobek m\u00e1 certifik\u00e1t o p\u016fvodu (IASC). Rozd\u00edl mezi aloe, kter\u00e9 vyrostlo na speci\u00e1ln\u00ed p\u016fd\u011b ve specifick\u00fdch p\u0159\u00edrodn\u00edch podm\u00ednk\u00e1ch a kdekoli jinde m\u016f\u017ee b\u00fdt takov\u00fd, jako mezi marihuanou a technick\u00fdm konop\u00edm. Krom\u011b toho, \u017ee ur\u010dit\u00e9 \u010d\u00e1sti listu jsou toxick\u00e9 a siln\u011b proj\u00edmav\u00e9, nen\u00ed vhodn\u00e9 pou\u017eit\u00ed u pacient\u016f s cukrovkou, p\u0159ed operacemi \u2013 vy\u0161\u0161\u00ed krv\u00e1civost, u srde\u010dn\u00edch onemocn\u011bn\u00ed tak\u00e9 pozor \u2013 zvy\u0161uje tepovou frekvenci, co\u017e m\u016f\u017ee kardiaka zab\u00edt. U onemocn\u011bn\u00ed HCM, kter\u00e9 se u ko\u010dek vyskytuje celkem \u010dasto nebo p\u0159i myopatii zp\u016fsoben\u00e9 virovou infekc\u00ed (nap\u0159\u00edklad FIP) m\u016f\u017ee vyvolat fat\u00e1ln\u00ed komplikace. D\u00e1le je ve h\u0159e probl\u00e9m se \u017elu\u010dn\u00edkem, po\u0161kozen\u00edm \u017ealudku a u ko\u010dek obecn\u011b velmi citliv\u00fdch na po\u0161kozen\u00ed ledvin m\u016f\u017ee b\u00fdt p\u0159\u00ed\u010dinou jejich selh\u00e1n\u00ed.<\/p>\n<p>Kukurma, resp. kukurmin v n\u00ed obsa\u017een\u00fd je nesm\u00edrn\u011b prosp\u011b\u0161n\u00fd a \u00fa\u010dinky na imunitu zejm\u00e9na u FeLV a FIV infekc\u00ed jsou v\u011bdecky potvrzen\u00e9. I tady v\u0161ak pozor. Krom\u011b toho, \u017ee m\u016f\u017ee vyvolat alergii, m\u016f\u017ee p\u0159i dlouhodob\u00e9m u\u017e\u00edv\u00e1n\u00ed zp\u016fsobit za\u017e\u00edvac\u00ed pot\u00ed\u017ee, zvracen\u00ed, intoxikaci jater a pr\u016fjem. Vy\u0161\u0161\u00ed d\u00e1vka m\u016f\u017ee st\u00e1t za vznikem v\u0159ed\u016f.<\/p>\n<p>T\u0159ezalka te\u010dkovan\u00e1 by nem\u011bla b\u00fdt pod\u00e1v\u00e1na ko\u010dk\u00e1m, na kter\u00e9 m\u016f\u017ee dopadnout slune\u010dn\u00ed z\u00e1\u0159en\u00ed, nesm\u00ed ven, ani do voli\u00e9ry nebo k oknu bez zatemn\u011bn\u00ed. Zp\u016fsobuje toti\u017e p\u0159ecitliv\u011blost poko\u017eky a v\u00e1\u017en\u00e9 sp\u00e1leniny hlavn\u011b na m\u00e9n\u011b osrst\u011bn\u00fdch \u010d\u00e1stech t\u011bla. U plemen jako je sphynx atp. je z tohoto d\u016fvodu kontraindikov\u00e1na. Krom\u011b toho op\u011bt p\u0159i del\u0161\u00edm u\u017e\u00edv\u00e1n\u00ed hroz\u00ed \u0161ed\u00fd z\u00e1kal, vysok\u00fd cholesterol, po\u0161kozen\u00ed jater, poruchy sp\u00e1nku, nedoporu\u010duje se diabetik\u016fm a velice rizikov\u00e9 je u\u017eit\u00ed u kardiak\u016f. I zdrav\u00fdm ko\u010dk\u00e1m m\u016f\u017ee vyvolat poruchy srde\u010dn\u00edho rytmu..<\/p>\n<p>Pokud budou produkty tohoto typu na vlasn\u00ed nebezpe\u010d\u00ed u\u017e\u00edv\u00e1ny s v\u011bdom\u00edm v\u0161ech rizik soub\u011b\u017en\u011b s ProBoostem, nelze jejich ne\u017e\u00e1douc\u00ed p\u016fsoben\u00ed p\u0159i\u010d\u00edtat TPA, ale pouze t\u011bmto produkt\u016fm. Soub\u011b\u017en\u00e9 pou\u017e\u00edv\u00e1n\u00ed lze doporu\u010dit pouze kr\u00e1tkodob\u011b nap\u0159\u00edklad b\u011bhem stabiliza\u010dn\u00ed f\u00e1ze nebo samoz\u0159ejm\u011b opakovan\u011b formou ozdravn\u00e9 k\u016fry a se z\u0159etelem na jejich vliv na dal\u0161\u00ed onemocn\u011bn\u00ed pacienta (cukrovka, nemoci srdce, jater, ledvin\u2026). Jedin\u011b tak mohou b\u00fdt opravdovou a \u00fa\u010dinnou pomoc\u00ed pro nemocn\u00e1 zv\u00ed\u0159ata a p\u0159edat jim z p\u0159\u00edrody sv\u00fdm prost\u0159ednictv\u00edm jen to pozitivn\u00ed.\u00a0<\/p>\n<p>\u00a0<\/p>\n\t\t\n<style>\n#text-1595738563 {\n  color: rgb(0,0,0);\n}\n#text-1595738563 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-638819929\">\n\n\n\t<div id=\"col-1784237460\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-3585766560\" class=\"text\">\n\t\t\n\n<p>O tom, \u017ee pod\u00e1v\u00e1n\u00ed TPA v\u00fdznamn\u011b ovliv\u0148uje kvalitu \u017eivota i celkovou progn\u00f3zu nemocn\u00fdch ko\u010dek nen\u00ed pochybnost, proto\u017ee pod veden\u00edm veterin\u00e1rn\u00edch l\u00e9ka\u0159\u016f touto terapi\u00ed pro\u0161ly zejm\u00e9na v USA, Kanad\u011b a ve Velk\u00e9 Brit\u00e1nii tis\u00edce ko\u010di\u010d\u00edch pacient\u016f. Prakticky v\u0161em ko\u010dk\u00e1m prosp\u00edv\u00e1 pod\u00e1v\u00e1n\u00ed ProBoostu, Thymic Protein A ke zlep\u0161en\u00ed celkov\u00e9ho zdravotn\u00edho stavu a utlumen\u00ed autoimunitn\u00edch i infek\u010dn\u00edch komplikac\u00ed, kter\u00e9 s sebou p\u0159in\u00e1\u0161\u00ed jejich imunosuprimovan\u00fd stav. V n\u011bkter\u00fdch p\u0159\u00edpadech zejm\u00e9na v po\u010d\u00e1te\u010dn\u00edm st\u00e1diu, kdy nemoc je\u0161t\u011b p\u0159\u00edli\u0161 nezdecimovala obranyschopnost a u mlad\u00fdch zv\u00ed\u0159at do\u0161lo k vymizen\u00ed viru z t\u011bla.<\/p>\n<p>Mnoho let byl v zahrani\u010d\u00ed pou\u017e\u00edv\u00e1n injek\u010dn\u00ed produkt LTCI. ProBoost je plnohodnotn\u00e1 n\u00e1hrada se stejnou \u00fa\u010dinnou l\u00e1tkou, ale rozd\u00edlnou formou pod\u00e1n\u00ed, tedy nikoliv injek\u010dn\u011b, ale peror\u00e1ln\u011b. Thymic Protein A, zkr\u00e1cen\u011b TPA, je jin\u00fdm pojmenov\u00e1n\u00edm t\u00e9\u017ee \u00fa\u010dinn\u00e9 l\u00e1tky v ProBoostu, kter\u00e1 se v p\u0159\u00edpad\u011b produktu firmy T-cyte jmenuje Lymphocyte T-Cell Immunomodulator, zkr\u00e1cen\u011b LTCI. V\u00fdrobcem je stejn\u00e1 firma, kter\u00e1 je dr\u017eitelem patent\u016f a odborn\u00fdm garantem a objevitelem je imunolog Dr. Terry Beardsley. Z hlediska \u00fa\u010dinnosti vzhledem k onemocn\u011bn\u00ed je peror\u00e1ln\u00ed a injek\u010dn\u00ed pod\u00e1v\u00e1n\u00ed rovnocenn\u00e9. I kdy\u017e p\u0159i pr\u016fchodu tr\u00e1v\u00edc\u00edm traktem doch\u00e1z\u00ed k jist\u00e9 destrukci, do krevn\u00edho ob\u011bhu pronikne dostatek intaktn\u00edch molekul, aby zajistilo po\u017eadovan\u00fd efekt. Je t\u0159eba oproti injek\u010dn\u00ed form\u011b vy\u0161\u0161\u00ed frekvence aplikace, zejm\u00e9na v po\u010d\u00e1te\u010dn\u00edm obdob\u00ed, aby byla nastavena a udr\u017eena stabiln\u00ed dostate\u010dn\u00e1 nab\u00eddka molekul TPA v krvi.<\/p>\n<p>Mechanismus p\u016fsoben\u00ed TPA v t\u011ble infikovan\u00e9 ko\u010dky je velmi komplexn\u00ed, slo\u017eit\u00fd a prob\u00edh\u00e1 na mnoha \u00farovn\u00edch.<\/p>\n<p>Pochopiteln\u011b je t\u0159eba za\u010d\u00edt od po\u010d\u00e1tku, tedy situac\u00ed p\u0159ed infekc\u00ed.<\/p>\n<p>Pokud se zdrav\u00e1 ko\u010dka setk\u00e1 s infekc\u00ed, m\u00e1 velmi siln\u00fd obrann\u00fd mechanismus, jak potla\u010dit nemoc je\u0161t\u011b p\u0159ed jej\u00edm propuknut\u00edm. Pravd\u011bpodobnost, \u017ee propukne akutn\u00ed f\u00e1ze infekce se v\u00fdrazn\u011b zvy\u0161uje, pokud imunitn\u00ed syst\u00e9m soub\u011b\u017en\u011b bojuje s dal\u0161\u00edmi chorobami, kter\u00e9 od\u010derp\u00e1vaj\u00ed drahocen\u00e9 s\u00edly. Je tedy na m\u00edst\u011b u zv\u00ed\u0159at, kter\u00e1 \u017eij\u00ed z pohledu mo\u017en\u00e9 infekce rizikov\u00fdm zp\u016fsobem \u017eivota smyslupln\u011b posilovat imunitu a udr\u017eovat je v dobr\u00e9m zdravotn\u00edm stavu. TPA pochopiteln\u011b nen\u00ed jedinou mo\u017enost\u00ed, jak tohoto stavu dos\u00e1hnout, nicm\u00e9n\u011b m\u016f\u017ee b\u00fdt vynikaj\u00edc\u00edm i jedin\u00fdm preventivn\u00edm ochrann\u00fdm prost\u0159edkem nap\u0159\u00edklad u venkovn\u00edch ko\u010dek, hlavn\u011b nekastrovan\u00fdch kocour\u016f, u ko\u010dek ve skupin\u00e1ch s v\u00fdskytem FIV apod. Pro\u010d je tomu tak bude vysv\u011btleno pokud mo\u017eno velmi zjednodu\u0161en\u011b v n\u00e1sleduj\u00edc\u00edm textu.<\/p>\n<p>V akutn\u00ed f\u00e1zi infekce a b\u011bhem dal\u0161\u00edho kvazi bezp\u0159\u00edznakov\u00e9ho obdob\u00ed je re\u00e1ln\u00e1 \u0161ance p\u0159i mobilizaci imunity infekci eliminovat. \u010c\u00edm d\u00e9le nemoc trv\u00e1, t\u00edm je tato mo\u017enost m\u00e9n\u011b pravd\u011bpodobn\u00e1. Virus napad\u00e1 bu\u0148ky imunitn\u00edho syst\u00e9mu a to zejm\u00e9na T a B lymfocyty. Postupn\u00e1 likvidace t\u011bchto bun\u011bk soub\u011b\u017en\u011b s destrukc\u00ed brzl\u00edku vede ke kolapsu imunity v termin\u00e1ln\u00ed f\u00e1zi. Proces, k n\u011bmu\u017e doch\u00e1z\u00ed a to, jak\u00fdm zp\u016fsobem do n\u011bj m\u016f\u017ee zas\u00e1hnout pod\u00e1v\u00e1n\u00ed TPA a zvr\u00e1tit nebo alespo\u0148 zlep\u0161it progn\u00f3zu je stru\u010dn\u011b a snad jednodu\u0161e vysv\u011btleno v n\u00e1sleduj\u00edc\u00edm textu psan\u00e9m kurz\u00edvou.<\/p>\n\t\t\n<style>\n#text-3585766560 {\n  color: rgb(0,0,0);\n}\n#text-3585766560 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-960301387\">\n\n\n\t<div id=\"col-1507553150\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-326089388\" class=\"text\">\n\t\t\n\n<p><em>Hlavn\u00ed bu\u0148ky adaptivn\u00ed imunity, tedy T lymfocyty vznikaj\u00ed v kostn\u00ed d\u0159eni. Nejsou ale funk\u010dn\u00ed, dokud nejsou selektov\u00e1ny tak, aby nenapadaly vlastn\u00ed tk\u00e1n\u011b t\u011bla, k \u010demu\u017e doch\u00e1z\u00ed v brzl\u00edku. B<\/em><em>\u011bhem nitrod\u011blo\u017en\u00edho v\u00fdvoje a brzo po narozen\u00ed a v ran\u00e9m ml\u00e1d\u00ed je vytvo\u0159ena z\u00e1sadn\u00ed z\u00e1soba t\u011bchto tzv. maturovan\u00fdch \u2013 vysp\u011bl\u00fdch a funkceschopn\u00fdch lymfocyt\u016f. Jak organismus st\u00e1rne, nov\u011b vy\u0161kolen\u00fdch lymfocyt\u016f dramaticky ub\u00fdv\u00e1. V brzl\u00edku\/thymu se nau\u010d\u00ed pozn\u00e1vat \u201esv\u00e9\u201c od \u201eciz\u00edho\u201c. Ty bu\u0148ky, kter\u00e9 to nedok\u00e1\u017eou a reaguj\u00ed na \u201esv\u00e9\u201c mus\u00ed zahynout. P\u0159e\u017eije jen mal\u00e9 procento \u201evy\u0161kolen\u00fdch\u201c maturovan\u00fdch T lymfocyt\u016f, kter\u00e9 pak tvo\u0159\u00ed v t\u011ble (uzliny, slezina) do\u017eivotn\u00ed z\u00e1sobu \u201eBlanick\u00fdch ryt\u00ed\u0159\u016f\u201c, kte\u0159\u00ed po aktiva\u010dn\u00edm sign\u00e1lu povstanou, rozmno\u017e\u00ed sv\u00e9 \u0159ady a spust\u00ed nev\u00eddan\u00fd \u00fatok a zni\u010d\u00ed v\u0161echny viry i napaden\u00e9 bu\u0148ky, v jejich\u017e nitru se viry skr\u00fdvaj\u00ed. Co nastane po infekci virem felinn\u00ed imunodeficience. Virov\u00e9 partikule selektivn\u011b napadaj\u00ed pr\u00e1v\u011b imunokompetentn\u00ed bu\u0148ky, krom\u011b CD4+ helper bun\u011bk tak\u00e9 CD8+ cytotoxick\u00e9 a dal\u0161\u00ed T a B lymfocyty a tak\u00e9 nap\u0159\u00edklad makrof\u00e1gy. Tedy cel\u00fd bun\u011b\u010dn\u00fd arzen\u00e1l nej\u00fa\u010dinn\u011bj\u0161\u00edho obrann\u00e9ho mechanismu t\u011bla, specifick\u00e9 adaptivn\u00ed imunity. T\u011blo nem\u00e1 jinou mo\u017enost obrany, ne\u017e ni\u010dit vlastn\u00ed napaden\u00e9 imunitn\u00ed bu\u0148ky. Dokud trv\u00e1 infekce kr\u00e1tce a brzl\u00edk je\u0161t\u011b pln\u00ed svou \u00falohu, m\u016f\u017ee t\u011blo zni\u010den\u00e9 bu\u0148ky nahrazovat, ohromn\u00e1 z\u00e1soba maturovan\u00fdch lymfocyt\u016f v uzlin\u00e1ch ub\u00fdv\u00e1 jenom pomalu a nemoc tak postupuje pouze pozvolna. \u010c\u00edm d\u00e9le v\u0161ak trv\u00e1, t\u00edm m\u00e9n\u011b zdrav\u00fdch krvinek zb\u00fdv\u00e1. Kostn\u00ed d\u0159e\u0148 se vy\u010derp\u00e1v\u00e1, proto\u017ee krom\u011b dopl\u0148ov\u00e1n\u00ed krvinek zni\u010den\u00fdch virem FIV mus\u00ed vyr\u00e1b\u011bt dal\u0161\u00ed a dal\u0161\u00ed krvinky pro boj s oportunn\u00edmi infekcemi. Brzl\u00edk degeneruje jak v\u011bkem, tak v d\u016fsledku destrukce virem FIV. Nov\u00e9 lymfocyty ji\u017e nedosp\u00edvaj\u00ed a jejich z\u00e1soba v m\u00edzn\u00edm syst\u00e9mu se postupn\u011b vy\u010derp\u00e1v\u00e1. Nav\u00edc d\u00edky regresi brzl\u00edku ji\u017e nedoch\u00e1z\u00ed k synt\u00e9ze informa\u010dn\u00edch molekul, transmitter\u016f, kter\u00e9 se na tvorb\u011b a aktivaci \u010dekaj\u00edc\u00edch naivn\u00edch lymfocyt\u016f v m\u00edzn\u00edch uzlin\u00e1ch pod\u00edlej\u00ed a t\u011blo boj s virem v d\u016fsledku absolutn\u00edho vy\u010derp\u00e1n\u00ed vzd\u00e1. Nem\u00e1 dostate\u010dn\u00fd potenci\u00e1l pro boj s infekcemi v\u0161eho druhu a nav\u00edc doch\u00e1z\u00ed k chyb\u00e1m, proto\u017ee kolabuje i \u0159\u00edd\u00edc\u00ed a kontroln\u00ed funkce zprost\u0159edkov\u00e1van\u00e1 T lymfocyty a autoimunitn\u00edmi procesy t\u011blo dokon\u010d\u00ed celou zk\u00e1zu. N\u011bkter\u00e9 bu\u0148ky se vymknou kontrole a za\u010dne malign\u00ed proces, kter\u00fd nem\u00e1 kdo zastavit.<\/em><\/p>\n<p><em>Je naprosto fascinuj\u00edc\u00ed, \u017ee t\u011blo disponuje schopnost\u00ed tuto apokalypsu zvr\u00e1tit. Ne jedinou, ale jednou z velmi dobr\u00fdch cest je v\u010dasn\u00e1 aktivace sp\u00edc\u00edch naivn\u00edch T lymfocyt\u016f pomoc\u00ed thymov\u00e9ho glykoproteinu A. Probuzen\u00ed v\u00edce CD4+ lymfocyt\u016f n\u00e1sobn\u011b zes\u00edl\u00ed aktivitu organismu v boji proti virov\u00e9 infekci. Pro\u010d to neud\u011bl\u00e1 s\u00e1m, bez vn\u011bj\u0161\u00ed stimulace nadbytkem stimula\u010dn\u00edch molekul? Prost\u011b proto, \u017ee t\u011blo t\u00edmto zp\u016fsobem reaguje na chronick\u00e9 infekce. Aktivita obrann\u00fdch mechanism\u016f se s p\u0159echodem do chronicity zmen\u0161uje. Velmi vzd\u00e1len\u011b a se zna\u010dnou m\u00edrou nads\u00e1zky lze tento stav p\u0159irovnat k habituaci na podn\u011bty, kter\u00e1 se \u010dasto vykl\u00e1d\u00e1 na p\u0159\u00edkladu hlem\u00fd\u017ed\u011b, kter\u00fd po ka\u017ed\u00e9m ot\u0159esu schov\u00e1 tykadla. Pokud se ale ot\u0159esy opakuj\u00ed p\u0159\u00edli\u0161 dlouho, hlem\u00fd\u017e\u010f je za\u010dne ignorovat. Nav\u00edc t\u011blo si nem\u016f\u017ee dovolit komfort vy\u010derpat v\u0161echny zdroje najednou, proto\u017ee mus\u00ed zajistit mnoho dal\u0161\u00edch ochrann\u00fdch funkc\u00ed. S t\u00edm tak\u00e9 po\u010d\u00edt\u00e1 dlouhodob\u00e1 virov\u00e1 strategie p\u0159e\u017eit\u00ed. Zni\u010den\u00edm sv\u00e9ho hostitele b\u011bhem akutn\u00ed f\u00e1ze infekce by zlikvidoval i s\u00e1m sebe. Proto je pro p\u0159e\u017eit\u00ed a \u0161\u00ed\u0159en\u00ed viru v\u00fdhodn\u011bj\u0161\u00ed chronick\u00e9 perzistov\u00e1n\u00ed a vyt\u011b\u017een\u00ed hostitele pomalu, ale \u00fa\u010dinn\u00fdm zp\u016fsobem d\u00edky utlumen\u00ed jeho obrann\u00e9 aktivity.<\/em><\/p>\n<p><em>Po aktivaci CD4+ dojde k cel\u00e9 kask\u00e1d\u011b d\u011bj\u016f, kter\u00e9 mohou cel\u00fd destruk\u010dn\u00ed proces zastavit nebo dokonce zvr\u00e1tit. CD4+ po obdr\u017een\u00ed sign\u00e1lu od bun\u011bk imunitn\u00edho syst\u00e9mu, kter\u00e9 se setkaly s virem FIV projdou aktiva\u010dn\u00edm procesem, na n\u011bm\u017e se pod\u00edl\u00ed i TPA. Z n\u011bkter\u00fdch aktivovan\u00fdch bun\u011bk se stanou <\/em><em>CD4+ Th1 lymfocyty, z n\u011bkter\u00fdch Th2. Oba typy se ujmou sv\u00e9 p\u0159\u00edslu\u0161n\u00e9 \u0159\u00edd\u00edc\u00ed funkce. Krom\u011b vys\u00edl\u00e1n\u00ed informa\u010dn\u00edch molekul s p\u0159\u00edkazy doch\u00e1z\u00ed k multiplikaci a klonov\u00e1n\u00ed sv\u00fdch funk\u010dn\u00edch kopi\u00ed, kter\u00e9 zes\u00edl\u00ed nal\u00e9havost vys\u00edlan\u00fdch informa\u010dn\u00edch sign\u00e1l\u016f jejich mno\u017estv\u00edm. D\u00edky tomu dojde k aktivaci CD8+ cytotoxick\u00fdch lymfocyt\u016f, kter\u00e9 za\u010dnou vyhled\u00e1vat a doslova rozpou\u0161t\u011bt napaden\u00e9 bu\u0148ky.\u00a0<\/em><em>CD4+ Th2 lymfocyty aktivuj\u00ed B lymfocyty, kter\u00e9<\/em><em>\u00a0za\u010dnou produkovat specifick\u00e9 protil\u00e1tky.\u00a0<\/em><em>Virov\u00e9 antigeny ozna\u010den\u00e9 protil\u00e1tkami se tak stanou atraktivn\u00ed pro celou arm\u00e1du fagocytuj\u00edc\u00edch bun\u011bk. Dal\u0161\u00ed instrukce dostane kostn\u00ed d\u0159e\u0148. Je t\u0159eba tvo\u0159it nov\u00e9 b\u00edl\u00e9 i \u010derven\u00e9 krvinky.. naroste po\u010det NK bun\u011bk a dal\u0161\u00edch krevn\u00edch element\u016f. Jako t\u0159e\u0161inka na dortu je informace, kterou p\u0159ed\u00e1v\u00e1 napaden\u00fdm b\u00edl\u00fdm krvink\u00e1m TPA. Po obdr\u017een\u00ed tohoto sign\u00e1lu napaden\u00e9 bu\u0148ky, kter\u00e9 maj\u00ed uvnit\u0159 sv\u00e9ho j\u00e1dra v\u010dlen\u011bnou virovou informaci a slou\u017e\u00ed jako v\u00fdrobn\u00ed tov\u00e1rna produkuj\u00edc\u00ed nov\u00e9 a nov\u00e9 virov\u00e9 partikule, uposlechnou p\u0159\u00edkaz a zah\u00e1j\u00ed proces apopt\u00f3zy, tedy jak\u00e9si \u0159\u00edzen\u00e9 sebevra\u017edy. Zdrav\u00e9 bu\u0148ky TPA v tomto smyslu nijak neovlivn\u00ed, tak\u017ee se d\u00e1l mohou pod\u00edlet na ozdravn\u00e9m procesu.<\/em><\/p>\n\t\t\n<style>\n#text-326089388 {\n  color: rgb(0,0,0);\n}\n#text-326089388 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-1497637246\">\n\n\n\t<div id=\"col-1309558552\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-3514921895\" class=\"text\">\n\t\t\n\n<p>Cel\u00fd pr\u00e1v\u011b popsan\u00fd proces je je\u0161t\u011b mnohon\u00e1sobn\u011b slo\u017eit\u011bj\u0161\u00ed, proto\u017ee jedna akce m\u00e1 za n\u00e1sledek n\u011bkolik mo\u017en\u00fdch reakc\u00ed v z\u00e1vislosti na okolnostech a je n\u011bkolikastup\u0148ov\u011b zp\u011btn\u011b kontrolovan\u00e1 nejen imunitn\u00edm syst\u00e9mem, ale i informacemi z dal\u0161\u00edch funk\u010dn\u00edch syst\u00e9m\u016f t\u011bla. Imunitn\u00ed syst\u00e9m neexistuje s\u00e1m, izolovan\u00fd od ostatn\u00edch \u017eivotn\u00edch proces\u016f, ale p\u0159ij\u00edm\u00e1 a vyhodnocuje ohromn\u00e9 mno\u017estv\u00ed informac\u00ed ze v\u0161ech stran.<\/p>\n\t\t\n<style>\n#text-3514921895 {\n  color: rgb(0,0,0);\n}\n#text-3514921895 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\t<div id=\"text-1040454865\" class=\"text\">\n\t\t\n\n<p>V\u00fdsledky experiment\u016f, kter\u00e9 potvrzuj\u00ed \u00falohu brzl\u00edkov\u00e9ho proteinu A v organismu jsou uvedeny v kapitole&nbsp; s n\u00e1zvem&nbsp;<a href=\"http:\/\/proboostnow.eu\/en_us\/clanky\/\">Publications<\/a>. Informace o \u00faloze CD4+ Th lymfocytu v imunitn\u00edm syst\u00e9mu v \u010dl\u00e1nku&nbsp;<a href=\"http:\/\/proboostnow.eu\/en_us\/cd4-th-lymfocyt\/\">Thymic Protein A aktivuje naivn\u00ed CD4+Th Lymfocyty.<\/a>&nbsp;Vliv TPA na bun\u011b\u010dnou apopt\u00f3zu v \u010dl\u00e1nku:&nbsp;<a href=\"http:\/\/proboostnow.eu\/en_us\/apoptoza\/\">Thymic Protein A stimuluje apopt\u00f3zu malign\u00edch a infikovan\u00fdch bun\u011bk<\/a>. Ovlivn\u011bn\u00ed hematopo\u00e9zy popisuje \u010dl\u00e1nek&nbsp;<a href=\"http:\/\/proboostnow.eu\/en_us\/thymic-protein-a-stimuluje-hematopoezu\/\">Thymic protein A stimuluje hematopo\u00e9zu v\u0161ech krevn\u00edch element\u016f<\/a>. V\u00fdsledky n\u011bkter\u00fdch experiment\u016f a review shrnuj\u00edc\u00ed z\u00edskan\u00e9 poznatky vlivu TPA\/LCTI na imunodeficientn\u00ed ko\u010dky naleznete v odkazu n\u00ed\u017ee.<\/p>\n<h1 style=\"text-align: center;\"><strong>\u2193<\/strong><\/h1>\n\t\t\n<style>\n#text-1040454865 {\n  color: rgb(0,0,0);\n}\n#text-1040454865 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n<div class=\"row\"  id=\"row-438732756\">\n\n\n\t<div id=\"col-968159218\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:rgb(213, 218, 232);\" >\n\t\t\t\n\t\t\t\n\n<a href=\"http:\/\/tcyte.com\/downloads\/ltci-review.pdf\" class=\"button primary is-outline box-shadow-5 box-shadow-5-hover\"  style=\"border-radius:10px;\">\n\t\t<span>Lymphocyte T-Cell Immunomodulator (LTCI): Review of the Immunopharmacology of a New Veterinary Biologic<\/span>\n\t<\/a>\n\n\n<a href=\"https:\/\/patents.google.com\/patent\/US5616554A\/en\" class=\"button primary is-outline box-shadow-5 box-shadow-5-hover expand\"  style=\"border-radius:10px;\">\n\t\t<span>EXAMPLE IV Clinical Protocol, Example V a VI<\/span>\n\t<\/a>\n\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\n<style>\n#row-438732756 > .col > .col-inner {\n  background-color: rgb(213, 218, 232);\n}\n<\/style>\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-582552046\">\n\n\n\t<div id=\"col-1126293888\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n<div class=\"row\"  id=\"row-507239372\">\n\n\n\t<div id=\"col-351492348\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:rgb(213, 218, 232);\" >\n\t\t\t\n\t\t\t\n\n<div class=\"row\"  id=\"row-955299116\">\n\n\n\t<div id=\"col-1021405073\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"gap-1500424135\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1500424135 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div id=\"gap-1793830724\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1793830724 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n<div class=\"row align-middle\"  id=\"row-259984824\">\n\n\n\t<div id=\"col-1512505206\" class=\"col medium-6 small-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-1695075379\" class=\"text\">\n\t\t\n\n<p style=\"text-align: center;\">V\u00fdsledky n\u011bkter\u00fdch v\u011bdeck\u00fdch experiment\u016f jsou pops\u00e1ny v \u010dl\u00e1nku :<\/p>\n<p style=\"text-align: center;\">&nbsp;<\/p>\n\t\t\n<style>\n#text-1695075379 {\n  color: rgb(0,0,0);\n}\n#text-1695075379 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n<a href=\"http:\/\/proboostnow.eu\/en_us\/co-je-thymic-protein-a\/\" class=\"button primary is-outline box-shadow-5 box-shadow-5-hover expand\"  style=\"border-radius:10px;\">\n\t\t<span>CO JE THYMIC PROTEIN A?<\/span>\n\t<\/a>\n\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-1060507093\" class=\"col medium-6 small-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"gap-1285584569\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1285584569 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_1319491529\">\n\t\t<a class=\"\" href=\"http:\/\/proboostnow.eu\/en_us\/co-je-thymic-protein-a\/\" >\t\t\t\t\t\t<div class=\"img-inner box-shadow-5 box-shadow-5-hover dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"681\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/pexels-pavel-danilyuk-8442533-1024x684.jpg\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/pexels-pavel-danilyuk-8442533-1024x684.jpg 1024w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/pexels-pavel-danilyuk-8442533-scaled-e1677853470131.jpg 300w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/pexels-pavel-danilyuk-8442533-768x513.jpg 768w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/pexels-pavel-danilyuk-8442533-1536x1025.jpg 1536w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/pexels-pavel-danilyuk-8442533-2048x1367.jpg 2048w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/pexels-pavel-danilyuk-8442533-scaled-e1677853470131-18x12.jpg 18w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/pexels-pavel-danilyuk-8442533-500x334.jpg 500w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/pexels-pavel-danilyuk-8442533-800x534.jpg 800w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/pexels-pavel-danilyuk-8442533-1280x854.jpg 1280w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/pexels-pavel-danilyuk-8442533-1920x1282.jpg 1920w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/pexels-pavel-danilyuk-8442533-510x340.jpg 510w\" sizes=\"auto, (max-width: 1020px) 100vw, 1020px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/a>\t\t\n<style>\n#image_1319491529 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\t<div id=\"gap-1078540905\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1078540905 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-730176681\">\n\n\n\t<div id=\"col-883047658\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n<div class=\"accordion\">\n\n\t<div id=\"accordion-2108946346\" class=\"accordion-item\">\n\t\t<a id=\"accordion-2108946346-label\" class=\"accordion-title plain\" href=\"#accordion-item-jak\u00e9-procesy-vyvol\u00e1-v-t\u011ble-nemocn\u00e9-ko\u010dky-tpa\" aria-expanded=\"false\" aria-controls=\"accordion-2108946346-content\" >\n\t\t\t<button class=\"toggle\" aria-label=\"Toggle\"><i class=\"icon-angle-down\"><\/i><\/button>\n\t\t\t<span>Jak\u00e9 procesy vyvol\u00e1 v t\u011ble nemocn\u00e9 ko\u010dky TPA<\/span>\n\t\t<\/a>\n\t\t<div id=\"accordion-2108946346-content\" class=\"accordion-inner\" aria-labelledby=\"accordion-2108946346-label\" >\n\t\t\t\n\n<ul>\n<li>TPA\u00a0p\u016fsob\u00ed jako diferencia\u010dn\u00ed sign\u00e1l k\u00a0zah\u00e1jen\u00ed\u00a0dozr\u00e1v\u00e1n\u00ed\u00a0(iniciace\u00a0maturace)\u00a0thymocyt\u016f,\u00a0co\u017e jsou\u00a0prekurzory\u00a0CD4+\u00a0T\u00a0lymfocyt\u016f,\u00a0kter\u00e9 vznikaj\u00ed v kostn\u00ed d\u0159eni.\u00a0V d\u016fsledku tohoto diferencia\u010dn\u00edho a selek\u010dn\u00edho procesu vznikaj\u00ed funk\u010dn\u00ed naivn\u00ed CD4+ Th lymfocyty (zral\u00e9 \u201eklidov\u00e9\u201c CD4+ Th lymfocyty, kter\u00e9 dosud nepro\u0161ly aktiva\u010dn\u00edm procesem po prezentaci antigenu) a signifikantn\u011b se tak zv\u00fd\u0161\u00ed jejich mno\u017estv\u00ed na periferii.\u00a0Z\u00e1rove\u0148 v dal\u0161\u00edm stupni TPA stimuluje jejich aktivaci a diferenciaci sm\u011brem k Th1 imunitn\u00edmu bun\u011b\u010dn\u00e9mu typu protivirov\u00e9 aktivity.\u00a0Aktivovan\u00fd lymfocyt okam\u017eit\u011b za\u010dne vys\u00edlat\u00a0chemick\u00e9 posly nesouc\u00ed instrukce k\u00a0ostatn\u00edm bu\u0148k\u00e1m, za\u010dne klonovat s\u00e1m sebe a tak zv\u00fd\u0161\u00ed po\u010det \u0159\u00edd\u00edc\u00edch d\u016fstojn\u00edk\u016f imunitn\u00ed arm\u00e1dy. Vys\u00edl\u00e1 velmi speci\u00e1ln\u00ed sign\u00e1ly, kter\u00e9 vedou k c\u00edlen\u00e9mu vyhled\u00e1v\u00e1n\u00ed a likvidaci bun\u011bk napaden\u00fdch virem i virov\u00fdch partikul\u00ed samotn\u00fdch. P\u0159i spr\u00e1vn\u011b nastaven\u00e9 imunitn\u00ed reakci je tento proces komplexn\u00ed a obrana je aktivov\u00e1na z mnoha sm\u011br\u016f.\u00a0V\u00fdznamn\u00fd efekt pod\u00e1v\u00e1n\u00ed TPA\u00a0tomto konkr\u00e9tn\u00edm p\u0159\u00edpad\u011b\u00a0je\u00a0i\u00a0v tom, \u017ee\u00a0pozitivn\u011b posiluje\u00a0pr\u00e1v\u011b tu \u010d\u00e1st imunitn\u00edho syst\u00e9mu, kter\u00fd virus napad\u00e1 a ni\u010d\u00ed.<\/li>\n<li>Aktivace cytotoxick\u00fdch CD8+ T lymfocyt\u016f helpery ( a p\u0159edchoz\u00ed aktivace Th1 diferenciace s p\u0159isp\u011bn\u00edm TPA) vede k likvidaci napaden\u00fdch bun\u011bk i s virem uvnit\u0159. CD8+ lymfocyt napadenou bu\u0148ku doslova rozpust\u00ed, stejn\u011b jako pavouk mouchu. Je tak rychle zastavena produkce nov\u00fdch virov\u00fdch partikul\u00ed.<\/li>\n<li>V \u0159et\u011bzci sign\u00e1l\u016f vyslan\u00fdch aktivovan\u00fdmi\u00a0CD4+ Th1\u00a0lymfocyty se zvy\u0161uje jejich p\u016fsoben\u00edm i mno\u017estv\u00ed\u00a0a aktivita\u00a0dal\u0161\u00edch imunitn\u00edch bun\u011bk, jako jsou NK bu\u0148ky (p\u0159irozen\u00ed zabij\u00e1ci), makrof\u00e1gy a dendritick\u00e9 bu\u0148ky, kter\u00e9 se pod\u00edlej\u00ed na boji s infekc\u00ed jin\u00fdm zp\u016fsobem. Z\u00e1rove\u0148 dojde k aktivaci produkce v\u0161ech krevn\u00edch element\u016f\u00a0a to specificky v z\u00e1vislosti na jejich aktu\u00e1ln\u00ed depleci. Interleukinov\u00e1 signalizace ovliv\u0148uje produkci\u00a0jak \u010derven\u00fdch\u00a0a\u00a0b\u00edl\u00fdch krvinek, tak i krevn\u00edch desti\u010dek.\u00a0Dopln\u011bn\u00ed deficitu n\u011bkter\u00fdch\u00a0krvinek\u00a0pak vede k\u00a0n\u00e1sobn\u011b vy\u0161\u0161\u00ed efektivit\u011b\u00a0boje\u00a0s infekc\u00ed, ale tak\u00e9\u00a0k regeneraci po\u0161kozen\u00ed, kter\u00e1\u00a0nemoc zp\u016fsobila. Stimulace kostn\u00ed d\u0159en\u011b k produkci v\u0161ech typ\u016f krvinek, kterou p\u0159es n\u011bkolik regula\u010dn\u00edch stup\u0148\u016f vyvol\u00e1v\u00e1 TPA je \u00fa\u010dinn\u00fdm mechanismem kompenzace anemie a pos\u00edlen\u00edm bun\u011b\u010dn\u00e9 imunitn\u00ed reakce na nemoc.<\/li>\n<li><a name=\"firstHeading\"><\/a><b>T<\/b><b>h1 typ diferenciace<\/b>\u00a0je\u00a0krom\u011b aktivace a proliferace CD8+ T lymfocyt\u016f\u00a0rovn\u011b\u017e zodpov\u011bdn\u00fd za produkci interferonu \u03b3,\u00a0TNF-\u03b2,\u00a0IL-2 a IL-12\u00a0a maximalizaci \u00fa\u010dinnosti zab\u00edjen\u00ed u makrof\u00e1g\u016f. Doch\u00e1z\u00ed k podpo\u0159e produkce IgG (opsonizuj\u00edc\u00ed protil\u00e1tky).\u00a0IFN-\u03b3\u00a0zvy\u0161uje produkci IL-12 dendritick\u00fdmi bu\u0148kami a makrof\u00e1gy a skrze pozitivn\u00ed zp\u011btnou vazbu, IL-12 stimuluje produkci\u00a0IFN gama\u00a0v Th\u00a0lymfocytech a t\u00edm podporuje diferenciaci v Th1 lymfocyty.\u00a0<a href=\"https:\/\/cs.wikipedia.org\/wiki\/Interferon_%CE%B3\">IFN-y<\/a>\u00a0tak\u00e9 inhibuje produkci IL-4, \u010d\u00edm\u017e inhibuje vznik Th2 lymfocyt\u016f.<\/li>\n<li>Cel\u00fd tento proces nen\u00ed chaotick\u00fd, ale podl\u00e9h\u00e1 p\u0159\u00edsn\u00e9 zp\u011btn\u00e9 vazb\u011b, aby nedo\u0161lo k p\u0159ehnan\u00e9 \u0161kodliv\u00e9 autoimunitn\u00ed destrukci.\u00a0Krom\u011b\u00a0<b>inhibi\u010dn\u00edho p\u016fsoben\u00ed cytokinov\u00e9 signalizace<\/b>\u00a0kontroluje aktivitu Th lymfocyt\u016f\u00a0i Tc lymfocyt\u016f<b>\u00a0regula\u010dn\u00ed podskupina Treg lymfocyt\u016f<\/b>. TPA jak ji\u017e bylo uvedeno stimuluje maturaci thymocyt\u016f na naivn\u00ed Th0 lymfocyty, kter\u00e9 jsou p\u0159\u00edm\u00fdmi prekurzory Treg lymfocyt\u016f. Touto cestou tedy posiluje zp\u011btnou kontrolu, aby nedo\u0161lo ke \u0161kodliv\u00e9mu vych\u00fdlen\u00ed imunitn\u00ed odpov\u011bdi.<\/li>\n<li>CD4+Th lymfocyty maj\u00ed z\u00e1sadn\u00ed roli v procesu,\u00a0kter\u00fd\u00a0<b>p\u016fsob\u00ed proti tzv. vy\u010derp\u00e1n\u00ed T bun\u011bk u chronick\u00fdch virov\u00fdch infekc\u00ed,\u00a0<\/b><b>jak\u00fdmi jsou jak FeLV tak FIV<\/b>. Vy\u010derp\u00e1n\u00ed m\u016f\u017ee b\u00fdt spu\u0161t\u011bno celou \u0159adou faktor\u016f jako je nap\u0159\u00edklad p\u0159etrv\u00e1vaj\u00edc\u00ed\u00a0dlouhodob\u00e9\u00a0vystaven\u00ed antigenu (= viru) a ztr\u00e1ta pomoci od\u00a0CD4+ Th\u00a0lymfocyt\u016f\u00a0(nap\u0159\u00edklad i jejich ni\u010den\u00edm virovou infekc\u00ed, k n\u00ed\u017e u obou onemocn\u011bn\u00ed doch\u00e1z\u00ed).\u00a0Vystaven\u00ed antigenu m\u00e1 tak\u00e9 efekt na pr\u016fb\u011bh vy\u010derp\u00e1n\u00ed, jeliko\u017e del\u0161\u00ed vystaven\u00ed nebo vy\u0161\u0161\u00ed mno\u017estv\u00ed antigenu m\u00e1 za n\u00e1sledek zhor\u0161en\u00ed vy\u010derp\u00e1n\u00ed. Pro rozvinut\u00ed vy\u010derp\u00e1n\u00ed je t\u0159eba kontinu\u00e1ln\u00ed vystaven\u00ed antigenu po dobu alespo\u0148 2-4 t\u00fddn\u016f. To znamen\u00e1, \u017ee\u00a0<b>\u010d\u00edm siln\u011bj\u0161\u00ed je\u00a0<\/b><b>chronick\u00e1\u00a0<\/b><b>infekce a \u010d\u00edm d\u00e9le trv\u00e1, t\u00edm v\u00edce paradoxn\u011b sl\u00e1bne reaktivita imunitn\u00edho syst\u00e9mu<\/b>.\u00a0<b>Stimulace CD4+\u00a0<\/b><b>Th<\/b><b>\u00a0lymfocyt\u016f\u00a0<\/b><b>pomoc\u00ed TPA v\u00fd\u0161e zm\u00edn\u011bn\u00fdmi mechanismy m\u016f\u017ee tento stav resetovat a vr\u00e1tit s\u00edlu imunitn\u00ed reakci na infekci<\/b>. Proto m\u00e1 ohromn\u00fd v\u00fdznam pod\u00e1v\u00e1n\u00ed TPA i b\u011bhem bezp\u0159\u00edznakov\u00fdch relativn\u011b ne\u0161kodn\u00fdch f\u00e1z\u00ed infekce.<\/li>\n<li>Tento mechanismus nen\u00ed v\u00fdmyslem \u010dlov\u011bka, ale funguje v p\u0159\u00edrod\u011b miliony let. TPA nen\u00ed n\u011bjak\u00fd um\u011bl\u00fd chemick\u00fd prost\u0159edek, kter\u00fd m\u016f\u017ee nap\u00e1chat v\u00edce \u0161kody ne\u017e u\u017eitku se spoustou vedlej\u0161\u00edch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f. P\u0159i pod\u00e1v\u00e1n\u00ed TPA za t\u00e9m\u011b\u0159 t\u0159icet let nebyly zaznamen\u00e1ny \u017e\u00e1dn\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky.<\/li>\n<\/ul>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n\n\t\t<\/div>\n\t<\/div>\n\t\n\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1829","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/pages\/1829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/comments?post=1829"}],"version-history":[{"count":0,"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/pages\/1829\/revisions"}],"wp:attachment":[{"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/media?parent=1829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}